Key clinical point: The combination of lenvatinib and pembrolizumab showed good activity against various advanced solid tumors, notably RCC.
Major finding: The overall response rate for patients with RCC at data cutoff was 63%.
Study details: Phase 1b study of 13 patients and phase 2 expansion study of 124 patients with RCC and other solid tumors.
Disclosures: The study was sponsored by Eisai with collaboration from Merck Sharp & Dohme. Dr. Taylor disclosed a consulting or advisory role for Bristol-Myers Squibb, Eisai, Array BioPharma, Loxo, Bayer, ArQule, Blueprint Medicines, Novartis, and Sanofi/Genzyme, and speakers bureau activities for BMS and Eisai.
Taylor MH et al. J Clin Oncol. 2020 Jan. 21 doi: 10.1200/JCO.19.01598.